| (Values in U.S. Thousands) | Sep, 2017 | Jun, 2017 | Mar, 2017 | Dec, 2016 | Sep, 2016 |
| Sales | 1,720 | 860 | 4,870 | 7,950 | 3,970 |
| Sales Growth | +100.00% | -82.34% | -38.74% | +100.25% | +16.08% |
| Net Income | -10,360 | -12,270 | -22,890 | -31,440 | -32,310 |
| Net Income Growth | +15.57% | +46.40% | +27.19% | +2.69% | -30.23% |
Cempra Inc
(CEMP)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance. Cempra Holdings, LLC is headquartered in Chapel Hill, North Carolina.